Can these medicines help food addiction?
Quick answer
GLP-1 medicines can affect appetite and food-related reward, but they are not established treatments for food addiction or binge-eating disorder. Evidence is still developing, so seek assessment for loss-of-control eating rather than self-medicating or changing a prescription.
GLP-1 medicines can reduce appetite and food cravings, and early studies suggest they may help some people with binge eating. However, “food addiction” is not an established standalone diagnosis, and these medicines are not approved treatments for it. Distressing loss of control deserves compassionate assessment, regular nourishment and appropriate psychological support.
What does “food addiction” mean?
Some people use the term to describe intense cravings, constant thoughts about food or feeling unable to stop eating. Those experiences are real and deserve support. The label remains debated: food is essential for life, and feeling drawn to rewarding food does not by itself establish an addiction. Describing eating only as faulty brain chemistry misses stress, sleep, restriction, trauma, food insecurity and the food environment.
Binge-eating disorder is a recognised condition involving recurring episodes of unusually large food intake with a sense of lost control and marked distress, without the regular compensatory behaviours typical of bulimia. It is not the same as enjoying food, occasional overeating or simply having a higher weight. Eating disorders can occur at any body size.
How might GLP-1 medicines affect cravings?
Glucagon-like peptide-1 (GLP-1) is a gut hormone involved in appetite and blood glucose regulation. Semaglutide mimics its action; tirzepatide also acts on a second gut-hormone pathway. These medicines can increase fullness and change responses to food cues. Some people describe less “food noise”, meaning intrusive or persistent thoughts about food.
Effects on brain reward pathways are plausible, but do not mean food is equivalent to an addictive drug or that these medicines cure an addiction. Feeling less hungry is also not the same as recovery from an eating disorder. Adequate nutrition, flexibility around food and emotional wellbeing remain important.
How strong is the treatment evidence?
Small trials and observational studies suggest GLP-1 medicines may reduce binge-eating symptom scores. A recent systematic review found encouraging results but also small samples and varied study methods. Evidence about sustained recovery, relapse, safety in different eating disorders and comparisons with established psychological treatment remains limited. Findings with liraglutide or semaglutide should not be treated as proof for tirzepatide.
These medicines are not licensed specifically for food addiction or binge-eating disorder. Results from weight-management trials do not establish them as eating-disorder treatments. A smaller appetite or a lower weight alone is not proof that loss of control or distress has resolved.
What support is recommended now?
A clinician should ask about loss of control, restriction, vomiting, laxative use, mood and physical health rather than judge by weight alone. Evidence-based care for binge eating includes guided self-help and, when needed, eating-disorder-focused cognitive behavioural therapy, a structured talking treatment addressing eating patterns and related thoughts. NICE advises against medicine as the sole treatment for an eating disorder.
Regular meals and snacks can reduce the restriction–binge cycle. Avoid compensating for a binge by fasting, and do not use appetite suppression to chase an ever-lower intake. If medication is appropriate for a separate obesity or diabetes indication, coordinate care with an eating-disorder-informed clinician and dietitian. A current or previous eating disorder needs explicit discussion before treatment.
When should you seek help?
Ask your GP for help if eating feels out of control, causes distress or involves secrecy, purging or severe restriction. You do not have to meet a weight threshold to deserve assessment. If medication is making it hard to eat enough, or eating fears are intensifying, contact your prescriber promptly.
Fainting, dehydration, repeated vomiting or severe weakness needs urgent assessment. Severe persistent abdominal pain while taking these medicines also needs urgent medical advice. Call 999 for collapse, chest pain or immediate danger from self-harm. Support should focus on safety and recovery, not blame or a number on the scales.
Sources & further reading
Reviewed by
Dr Chinnadorai Rajeswaran
Specialist Endocrinologist · MBBS MRCP FRCP
Last Reviewed: November 2026
Read about complex severe obesity and related care.
Related insights
Weight Regain After GLP-1 Treatment: Why It Happens
Weight regain after stopping GLP-1 treatment is common because appetite and weight-regulating biology persist, though individual responses differ. Discuss a long-term plan with the prescriber before stopping or restarting, and do not alter doses independently.
Foundayo (Orforglipron): What a Daily Tablet Changes
Foundayo is a once-daily orforglipron tablet licensed in the UK, offering an oral route without the fasting routine required for oral semaglutide. Taking a tablet rather than an injection does not remove the need for a doctor to assess suitability, monitor side effects and review ongoing treatment.
Oral or Injectable GLP-1: How We Choose a Route
Oral and injectable GLP-1 medicines differ in absorption, dosing, evidence, and practical considerations; neither route is automatically best for everyone. A prescriber should choose based on the specific product, medical history, preferences, and local approval, with instructions followed exactly.